公开(公告)号：US09975903B2

公开(公告)日：2018-05-22

申请号：US15539607

申请日：2015-12-24

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Minoru Sasaki ,  Fumiaki Kikuchi ,  Zenichi Ikeda ,  Keiko Kakegawa ,  Yoichi Nishikawa ,  Shigekazu Sasaki ,  Koichiro Fukuda ,  Kazuaki Takami ,  Yoshihiro Banno ,  Masahiro Kamaura

IPC: C07D493/04 ,  C07D495/04 ,  C07D321/00 ,  C07D405/06 ,  C07D321/12 ,  C07D413/06 ,  C07D323/00 ,  C07D491/044 ,  C07D313/00 ,  C07D313/20

CPC classification number: C07D495/04 ,  A61K31/365 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/422 ,  A61K31/662 ,  C07D313/00 ,  C07D313/20 ,  C07D321/00 ,  C07D321/12 ,  C07D323/00 ,  C07D405/06 ,  C07D409/12 ,  C07D413/06 ,  C07D491/044 ,  C07D493/04 ,  C07F9/655

Abstract: The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (I) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification].

公开(公告)号：US20170226137A1

公开(公告)日：2017-08-10

申请号：US15421702

申请日：2017-02-01

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tatsuhiko Fujimoto ,  Kentaro Rikimaru ,  Koichiro Fukuda ,  Hiromichi Sugimoto ,  Takahiro Matsumoto ,  Norihito Tokunaga ,  Mariko Hirozane

IPC: C07F7/18 ,  C07D211/24 ,  C07D401/14 ,  C07D405/06 ,  C07D413/06 ,  C07D405/14 ,  C07D401/06 ,  C07D409/12 ,  C07D401/12 ,  C07D405/12 ,  C07D417/06 ,  C07D417/14 ,  C07D211/56 ,  C07D409/06

CPC classification number: C07F7/1804 ,  C07D211/24 ,  C07D211/36 ,  C07D211/56 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/14

Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.

公开(公告)号：US12077522B2

公开(公告)日：2024-09-03

申请号：US17256330

申请日：2019-06-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tatsuhiko Fujimoto ,  Koichiro Fukuda ,  Hiromichi Sugimoto ,  Kentaro Rikimaru ,  Yoshihiro Banno ,  Takahiro Matsumoto ,  Norihito Tokunaga ,  Yoshihide Tomata ,  Yuji Ishichi ,  Shogo Marui ,  Tsuneo Oda ,  Tohru Miyazaki ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Yuichi Kajita ,  Yuhei Miyanohana ,  Tatsuki Koike

IPC: C07D401/14 ,  C07D211/56 ,  C07D405/14

CPC classification number: C07D401/14 ,  C07D211/56 ,  C07D405/14

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US10508083B2

公开(公告)日：2019-12-17

申请号：US16075240

申请日：2017-02-01

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tatsuhiko Fujimoto ,  Kentaro Rikimaru ,  Koichiro Fukuda ,  Hiromichi Sugimoto ,  Takahiro Matsumoto

IPC: C07D211/36 ,  A61P25/00

Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.

公开(公告)号：US20190119225A1

公开(公告)日：2019-04-25

申请号：US16230634

申请日：2018-12-21

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yoshihiro Banno ,  Masahiro Kamaura ,  Kazuaki Takami ,  Koichiro Fukuda ,  Shigekazu Sasaki

IPC: C07D263/46 ,  C07D213/70 ,  A61P27/02 ,  C07D239/34 ,  A61K31/421 ,  C07D213/65 ,  C07D263/38 ,  A61K31/415 ,  C07D231/22 ,  C07D231/12 ,  A61K31/505 ,  A61K31/4418

Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.